Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 20840755)

1.

Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma.

Papazisis KT, Kontovinis LF, Papandreou CN, Kouvatseas G, Lafaras C, Antonakis E, Christopoulou M, Andreadis C, Mouratidou D, Kortsaris AH.

BMC Cancer. 2010 Sep 14;10:489. doi: 10.1186/1471-2407-10-489.

2.

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.

Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH.

BMC Cancer. 2009 Mar 12;9:82. doi: 10.1186/1471-2407-9-82.

3.

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.

Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U.

Oncology. 2009;76(5):350-4. doi: 10.1159/000209961. Epub 2009 Mar 24.

PMID:
19321976
4.

Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy.

Staehler M, Haseke N, Zilinberg K, Stadler T, Stief CG.

Urol Int. 2010;84(1):119-21. doi: 10.1159/000273480. Epub 2010 Feb 17.

PMID:
20173383
5.

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E.

Br J Cancer. 2010 Mar 2;102(5):803-9. doi: 10.1038/sj.bjc.6605567. Epub 2010 Feb 9.

6.

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.

Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H.

Jpn J Clin Oncol. 2010 Mar;40(3):194-202. doi: 10.1093/jjco/hyp146. Epub 2009 Nov 7.

7.
8.

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.

Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T.

BJU Int. 2012 May;109(9):1349-54. doi: 10.1111/j.1464-410X.2011.10534.x. Epub 2011 Aug 25.

PMID:
21883864
9.

[Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice].

Zhang QY, Du JB, Chen YH, Li WZ.

Zhonghua Er Ke Za Zhi. 2006 Dec;44(12):886-90. Chinese.

PMID:
17254452
10.
11.

Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels.

Jarai R, Fellner B, Haoula D, Jordanova N, Heinz G, Karth GD, Huber K, Geppert A.

Crit Care Med. 2009 Jun;37(6):1837-44. doi: 10.1097/CCM.0b013e31819fe896.

PMID:
19384228
12.

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.

Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA.

Eur J Cancer. 2012 May;48(7):1031-7. doi: 10.1016/j.ejca.2012.02.050. Epub 2012 Mar 10.

PMID:
22409947
13.

N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension.

Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T.

Am J Cardiol. 2006 Aug 15;98(4):525-9. Epub 2006 Jun 28.

PMID:
16893710
14.

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.

Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ.

J Transl Med. 2007 Jul 2;5:32.

15.

Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.

Szmit S, Langiewicz P, Złnierek J, Nurzyński P, Zaborowska M, Filipiak KJ, Opolski G, Szczylik C.

Kidney Blood Press Res. 2012;35(1):18-25. doi: 10.1159/000329933. Epub 2011 Aug 18.

PMID:
21849795
16.

High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is associated with an increased risk of in-hospital mortality and cardiogenic shock.

Vergès B, Zeller M, Desgrès J, Dentan G, Laurent Y, Janin-Manificat L, L'Huillier I, Rioufol G, Beer JC, Makki H, Rochette L, Gambert P, Cottin Y.

Eur Heart J. 2005 Sep;26(17):1734-41. Epub 2005 Apr 14.

17.

Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy.

Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, Collinson PO, McKenna WJ, Elliott PM.

Am J Cardiol. 2006 Aug 15;98(4):515-9. Epub 2006 Jun 27.

PMID:
16893708
18.

Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment.

Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA.

Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96.

PMID:
9373449
19.

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

D' Alterio C, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S.

Curr Cancer Drug Targets. 2012 Jul;12(6):693-702.

PMID:
22463589
20.

N-terminal pro B-type natriuretic peptide (NT pro-BNP) is a predictor of long-term survival in male patients of 75 years and older with high-grade asymptomatic internal carotid artery stenosis.

Duschek N, Skrinjar E, Waldhör T, Vutuc C, Daniel G, Hübl W, Assadian A.

J Vasc Surg. 2011 May;53(5):1242-50. doi: 10.1016/j.jvs.2010.10.123. Epub 2011 Jan 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk